Standard
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa : A Danish nationwide cohort study. / Ring, Hans Christian; Thorsen, Jonathan; Kirby, Brian; Ingram, John R; Rosenø, Nana Aviaaja Lippert; Holgersen, Nikolaj; Nielsen, Valdemar W; Nikolai Thein Aagaard, David; Maul, Julia-Tatjana; Wu, Jashin J; Thyssen, Jacob P; Egeberg, Alexander; Thomsen, Simon F.
I:
British Journal of Dermatology, Supplement, 2024.
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Harvard
Ring, HC
, Thorsen, J, Kirby, B, Ingram, JR, Rosenø, NAL, Holgersen, N, Nielsen, VW, Nikolai Thein Aagaard, D, Maul, J-T, Wu, JJ
, Thyssen, JP, Egeberg, A & Thomsen, SF 2024, '
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: A Danish nationwide cohort study',
British Journal of Dermatology, Supplement.
https://doi.org/10.1093/bjd/ljae042APA
Ring, H. C.
, Thorsen, J., Kirby, B., Ingram, J. R., Rosenø, N. A. L., Holgersen, N., Nielsen, V. W., Nikolai Thein Aagaard, D., Maul, J-T., Wu, J. J.
, Thyssen, J. P., Egeberg, A., & Thomsen, S. F. (2024).
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: A Danish nationwide cohort study.
British Journal of Dermatology, Supplement.
https://doi.org/10.1093/bjd/ljae042Vancouver
Ring HC
, Thorsen J, Kirby B, Ingram JR, Rosenø NAL, Holgersen N o.a.
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: A Danish nationwide cohort study.
British Journal of Dermatology, Supplement. 2024.
https://doi.org/10.1093/bjd/ljae042Author
Ring, Hans Christian ; Thorsen, Jonathan ; Kirby, Brian ; Ingram, John R ; Rosenø, Nana Aviaaja Lippert ; Holgersen, Nikolaj ; Nielsen, Valdemar W ; Nikolai Thein Aagaard, David ; Maul, Julia-Tatjana ; Wu, Jashin J ; Thyssen, Jacob P ; Egeberg, Alexander ; Thomsen, Simon F. / Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa : A Danish nationwide cohort study. I: British Journal of Dermatology, Supplement. 2024.
Bibtex
@article{433bd4d76b7f4af18b087d7b6d99c423,
title = "Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: A Danish nationwide cohort study",
author = "Ring, {Hans Christian} and Jonathan Thorsen and Brian Kirby and Ingram, {John R} and Rosen{\o}, {Nana Aviaaja Lippert} and Nikolaj Holgersen and Nielsen, {Valdemar W} and {Nikolai Thein Aagaard}, David and Julia-Tatjana Maul and Wu, {Jashin J} and Thyssen, {Jacob P} and Alexander Egeberg and Thomsen, {Simon F}",
year = "2024",
doi = "10.1093/bjd/ljae042",
language = "English",
journal = "British Journal of Dermatology, Supplement",
issn = "0366-077X",
publisher = "Wiley-Blackwell",
}
RIS
TY - JOUR
T1 - Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa
T2 - A Danish nationwide cohort study
AU - Ring, Hans Christian
AU - Thorsen, Jonathan
AU - Kirby, Brian
AU - Ingram, John R
AU - Rosenø, Nana Aviaaja Lippert
AU - Holgersen, Nikolaj
AU - Nielsen, Valdemar W
AU - Nikolai Thein Aagaard, David
AU - Maul, Julia-Tatjana
AU - Wu, Jashin J
AU - Thyssen, Jacob P
AU - Egeberg, Alexander
AU - Thomsen, Simon F
PY - 2024
Y1 - 2024
U2 - 10.1093/bjd/ljae042
DO - 10.1093/bjd/ljae042
M3 - Comment/debate
C2 - 38305415
JO - British Journal of Dermatology, Supplement
JF - British Journal of Dermatology, Supplement
SN - 0366-077X
ER -
